Activation of JAK2/STAT3 signaling in pancreatic cancer can lead to tumorigenesis, progression, cancer stem cell maintenance, and treatment resistance (Tyagi et al. 2016). This evidence concerns the gene JAK2 and familial pancreatic carcinoma.